NCT03199677 is a Phase 2 clinical trial of Apatinib in Refractory Cancer, sponsored by Chinese Academy of Medical Sciences.

Who is sponsoring NCT03199677?

NCT03199677 is sponsored by Chinese Academy of Medical Sciences.

What drugs are being tested in NCT03199677?

Interventions in NCT03199677: Apatinib.

What condition does NCT03199677 study?

NCT03199677 studies Refractory Cancer.

Is NCT03199677 still recruiting?

NCT03199677 is currently status unknown. Last updated 2 July 2017.

Last reviewed 2017-07-02 · How we verify

NCT03199677

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer

Status unknown Phase 2 Last updated 2 July 2017

What this trial tests

Phase 2 trial testing Apatinib in Refractory Cancer in 40 participants. Status unknown.

Timeline

1 July 2017

Primary endpoint
30 June 2018

30 June 2018

Quick facts

Lead sponsor	Chinese Academy of Medical Sciences
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 July 2017
Primary completion	30 June 2018
Estimated completion	30 June 2018
Sites	1 location across China

Drugs / interventions tested

Apatinib (Apatinib) — full drug profile →

Conditions studied

Refractory Cancer — all drugs for Refractory Cancer →

Sponsor

Chinese Academy of Medical Sciences — full company profile →

Who can join

Adults 18 to 75, any sex, with Refractory Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, open-label, single arm，exploratory clinical trial evaluating the efficacy and safety of Apatinib in patients with local progressive/metastatic refractory thyroid cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
Tirrò E, Martorana F, Romano C, Vitale SR, et al · · 2019 · cited 63× · PMID 31540307 · DOI 10.3390/genes10090709
Systemic treatments for radioiodine-refractory thyroid cancers.
Chen P, Yao Y, Tan H, Li J. · · 2024 · cited 6× · PMID 39473507 · DOI 10.3389/fendo.2024.1346476
Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.
Su JY, Huang T, Zhang JL, Lu JH, et al · · 2024 · cited 1× · PMID 38455407 · DOI 10.62347/ejaa3388

Verify or expand the search:

Other trials of Apatinib

Trials testing the same drug.

NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07031154 — A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Rese · Phase 2 · not yet recruiting
NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting

Other recruiting trials for Refractory Cancer

Currently open trials in the same condition.

NCT06634589 — A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relap · Phase 1, PHASE2 · recruiting
NCT06096038 — Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC · Phase 1, PHASE2 · recruiting
NCT06184035 — A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer · Phase 1, PHASE2 · recruiting
NCT05852717 — Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed · Phase 2 · recruiting
NCT06104488 — A Study of Avutometinib for People With Solid Tumor Cancers · Phase 1 · recruiting

Other Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03199677 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
Last refreshed: 2 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03199677.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing